UCB

Biotechnology / Pharmaceuticals
UCB.BR
€ 69 3.7
Share price
$ 13 bn
Market Cap
$ 15 bn
Enterprise Value

Carbon footprint

3 Ton
GHG emissions per $ 1 mln investment
0.08x the weighted average for S&P 500
FY2021
How is this calculated?
-5.2%
YOY change in GHG emissions
Weaker than the +4.9% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-11%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Stronger than the -6.6% weighted average for S&P 500
FY2022
How is this calculated?

UCB aims to achieve net zero for Scope 1 + 2 by 2030


This target has not been verified as science based according to SBTi
UCB's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

Secondary Climate Goal

UCB aims to reduce all Scopes by 38% by 2030 from a base year 2015


<2°C

GHG emissions and Carbon intensity

UCB's GHG emissions (location-based) (Kt of CO2e)
UCB's Carbon intensity (Tons per 1 USDm)

UCB's carbon footprint

UCB reported Total CO2e Emissions - Location-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 46 Kt (-2.5 /-5.2% y-o-y). Also positively, carbon intensity declined to 7.1 t (-1.1 /-13.4% y-o-y).

UCB's Scope 3 emissions decreased to 34 Kt (-4.2 /-11% y-o-y). The rate of decline has slowed vs. the previous periods (CAGR -20.6% since 4Q'18).

The company is committed to achieving net zero for Scope 1 + 2 by 2030, which translates into the estimated reduction of -5.1 Kt per annum over the period of FY2022 - FY2030. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Company environmental metrics

Show more...